Prurigo Nodularis Clinical Trials

87 clinical trials for Prurigo Nodularis across international registries, including 21 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Efficacy of Topical Cannabidiol for Eczema — RECRUITING · PHASE2
• Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis — RECRUITING · PHASE2
• SWITCH project: Definition of treat-to-target criteria for shared decision making between patients and physicians about initiating, continuing or switching systemic treatment for chronic prurigo and chronic pruritus — RECRUITING
• Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults — RECRUITING
• Use of the WHO-5 in chronic pruritus and chronic prurigo and development of a skin well-being questionnaire — RECRUITING
• Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis — RECRUITING · PHASE2
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis — RECRUITING · PHASE3
• Definition of Severity and Descriptors of Chronic Prurigo – Harmonization of European Prurigo Documentation — RECRUITING
• A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis — RECRUITING · PHASE3
• Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis — RECRUITING
• Determinants of Chronic Inflammatory Skin Disease Trajectories — RECRUITING
• Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis — RECRUITING · PHASE3
• China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project — RECRUITING
• SELECTIVE TREATMENT OF ORAL POVORCITINIB IN PRURIGO NODULARIS STUDY 2 (STOPPN2). A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF POVORCITINIB IN PARTICIPANTS WITH PRURIGO NODULARIS. — RECRUITING · PHASE3
• SELECTIVE TREATMENT OF ORAL POVORCITINIB IN PRURIGO NODULARIS STUDY 1 (STOP-PN1). A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF POVORCITINIB IN PARTICIPANTS WITH PRURIGO NODULARIS. — RECRUITING · PHASE3
• A PHASE 3, 52-WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLEBLIND STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF ROCATINLIMAB IN ADULT SUBJECTS WITH PRURIGO NODULARIS WHO ARE INADEQUATELY CONTROLLED ON TOPICAL THERAPIES OR NOT ELIGIBLE FOR TOPICAL THERAPIES — RECRUITING · PHASE3
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH PRURIGO NODULARIS — RECRUITING · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NEMOLIZUMAB (CD14152) IN SUBJECTS WITH PRURIGO NODULARIS — RECRUITING
• A PROSPECTIVE, MULTICENTER, LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF NEMOLIZUMAB (CD14152) IN SUBJECTS WITH PRURIGO NODULARIS — RECRUITING
• Acceptance and benefit of pruritus measurement in dermatological routine care — RECRUITING
• European Prurigo Project (EPP) of the EADV Task Force Pruritus — RECRUITING
• Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo Nodularis — COMPLETED · PHASE2
• Apremilast as anti-pruritic treatment in patients with prurigo nodularis — COMPLETED · PHASE2
• Nalbuphine HCL ER Tablets in Prurigo Nodularis Patients — COMPLETED · PHASE2
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis — TERMINATED · PHASE2
• A Study of Barzolvolimab in Patients With Prurigo Nodularis — ACTIVE_NOT_RECRUITING · PHASE2
• A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine — ACTIVE_NOT_RECRUITING
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis — TERMINATED · PHASE3
• A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies — OTHER · PHASE3
• Validation of a prurigo activity score — OTHER
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases — COMPLETED · PHASE1
• Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients — NOT_YET_RECRUITING · PHASE2
• Study on the Treatment of Prurigo Nodularis With Stapokibart Injection — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) — ACTIVE_NOT_RECRUITING · PHASE3
• Upadacitinib for Prurigo Nodularis — TERMINATED · PHASE4
• Gene regulation in pruritic diseases — OTHER
• Definition of the “itch controlled state” for patients with chronic prurigo — OTHER
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) — ACTIVE_NOT_RECRUITING · PHASE3
• CDX0159-10: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo Nodularis — TERMINATED · PHASE2
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis — TERMINATED · PHASE3
• Influence of scratching on skin profiles in chronic pruritus patients — OTHER
• Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis — COMPLETED · PHASE2
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) — COMPLETED · PHASE3
• A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis — TERMINATED · PHASE3
• Determination of the minimal clinical important difference (MCID) and its correlation with objective criteria of neuroanatomy in patients with chronic pruritus and dry skin under topical dermatotherapy - Subproject: Identification of relevant genes for neuroanatomy in the skin — OTHER
• Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life — COMPLETED · NA
• A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) — ACTIVE_NOT_RECRUITING · PHASE3
• Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study — ACTIVE_NOT_RECRUITING
• A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream — COMPLETED · PHASE1
• A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis — COMPLETED · PHASE2

Refine this search